SAGE THERAPEUTICS INC's ticker is SAGE and the CUSIP is 78667J108. A total of 253 filers reported holding SAGE THERAPEUTICS INC in Q1 2018. The put-call ratio across all filers is 0.89 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $99 | +5.3% | 4,789 | +140.8% | 0.00% | – |
| Q2 2023 | $94 | -10.5% | 1,989 | -20.6% | 0.00% | – |
| Q1 2023 | $105 | +9.4% | 2,505 | 0.0% | 0.00% | – |
| Q4 2022 | $96 | -99.9% | 2,505 | 0.0% | 0.00% | – |
| Q3 2022 | $98,000 | +21.0% | 2,505 | 0.0% | 0.00% | – |
| Q2 2022 | $81,000 | -8.0% | 2,505 | 0.0% | 0.00% | – |
| Q1 2022 | $88,000 | -30.7% | 2,505 | -16.4% | 0.00% | – |
| Q4 2021 | $127,000 | -5.2% | 2,997 | 0.0% | 0.00% | – |
| Q3 2021 | $134,000 | -21.2% | 2,997 | 0.0% | 0.00% | – |
| Q2 2021 | $170,000 | -33.9% | 2,997 | -13.2% | 0.00% | -100.0% |
| Q1 2021 | $257,000 | -13.8% | 3,453 | 0.0% | 0.00% | 0.0% |
| Q4 2020 | $298,000 | +41.2% | 3,453 | 0.0% | 0.00% | – |
| Q3 2020 | $211,000 | +47.6% | 3,453 | 0.0% | 0.00% | – |
| Q2 2020 | $143,000 | +43.0% | 3,453 | 0.0% | 0.00% | – |
| Q1 2020 | $100,000 | -59.5% | 3,453 | 0.0% | 0.00% | -100.0% |
| Q4 2019 | $247,000 | -78.1% | 3,453 | -43.9% | 0.00% | -66.7% |
| Q2 2019 | $1,126,000 | +13.6% | 6,156 | -1.5% | 0.00% | 0.0% |
| Q1 2019 | $991,000 | +88.8% | 6,251 | +10.1% | 0.00% | +50.0% |
| Q4 2018 | $525,000 | -28.4% | 5,677 | +9.5% | 0.00% | 0.0% |
| Q3 2018 | $733,000 | -9.7% | 5,186 | 0.0% | 0.00% | 0.0% |
| Q2 2018 | $812,000 | -3.0% | 5,186 | 0.0% | 0.00% | 0.0% |
| Q1 2018 | $837,000 | +22.4% | 5,186 | +24.6% | 0.00% | 0.0% |
| Q4 2017 | $684,000 | +162.1% | 4,162 | 0.0% | 0.00% | +100.0% |
| Q3 2017 | $261,000 | -21.1% | 4,162 | 0.0% | 0.00% | 0.0% |
| Q2 2017 | $331,000 | +12.2% | 4,162 | 0.0% | 0.00% | 0.0% |
| Q1 2017 | $295,000 | +38.5% | 4,162 | 0.0% | 0.00% | 0.0% |
| Q4 2016 | $213,000 | -44.2% | 4,162 | -50.0% | 0.00% | 0.0% |
| Q3 2016 | $382,000 | +205.6% | 8,324 | +100.0% | 0.00% | – |
| Q2 2016 | $125,000 | -6.0% | 4,162 | 0.0% | 0.00% | – |
| Q1 2016 | $133,000 | +155.8% | 4,162 | +365.0% | 0.00% | – |
| Q4 2015 | $52,000 | +36.8% | 895 | 0.0% | 0.00% | – |
| Q3 2015 | $38,000 | -41.5% | 895 | 0.0% | 0.00% | – |
| Q2 2015 | $65,000 | – | 895 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| GREAT POINT PARTNERS LLC | 1,966,688 | $120,204,000 | 10.81% |
| Integral Health Asset Management, LLC | 230,000 | $14,058,000 | 4.30% |
| Asymmetry Capital Management, L.P. | 102,462 | $6,262,000 | 4.02% |
| ACUTA CAPITAL PARTNERS, LLC | 225,000 | $13,752,000 | 3.74% |
| DAFNA Capital Management LLC | 158,306 | $9,676,000 | 3.14% |
| Bain Capital Life Sciences Investors, LLC | 499,100 | $30,505,000 | 2.84% |
| Boxer Capital, LLC | 1,094,000 | $66,865,000 | 2.31% |
| Palo Alto Investors LP | 590,200 | $36,073,000 | 1.98% |
| Logos Global Management LP | 250,000 | $15,280,000 | 1.96% |
| Bellevue Group AG | 1,579,504 | $96,539,000 | 1.33% |